Morris, V. K., Ciombor, K. K., Salem, M. E., Nimeiri, H. S., Iqbal, S., Singh, P. P., … Eng, C. (2016). NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). In Journal of Clinical Oncology (Vol. 34, pp. 3503–3503). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.3503

Morris, Van Karlyle, Kristen Keon Ciombor, Mohamed E. Salem, Halla Sayed Nimeiri, Syma Iqbal, Preet Paul Singh, Blase N. Polite, et al. “NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).” In Journal of Clinical Oncology, 34:3503–3503. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3503.

Morris VK, Ciombor KK, Salem ME, Nimeiri HS, Iqbal S, Singh PP, et al. NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3503–3503.

Morris, Van Karlyle, et al. “NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 3503–3503. Crossref, doi:10.1200/jco.2016.34.15_suppl.3503.

Morris VK, Ciombor KK, Salem ME, Nimeiri HS, Iqbal S, Singh PP, Polite BN, Deming DA, Chan E, Wade JL, Bekaii-Saab TS, Uronis HE, Pasia MG, Bland G, Wolff RA, Ohinata A, Ohaji C, Rogers J, Sharma P, Eng C. NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3503–3503.